Provided by Tiger Trade Technology Pte. Ltd.

Editas Medicine

3.16
-0.1400-4.24%
Post-market: 3.14-0.0193-0.61%19:52 EDT
Volume:3.27M
Turnover:10.77M
Market Cap:483.48M
PE:-4.32
High:3.41
Open:3.25
Low:3.15
Close:3.30
52wk High:4.54
52wk Low:1.66
Shares:153.00M
Float Shares:115.00M
Volume Ratio:1.17
T/O Rate:2.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7307
EPS(LYR):-1.8036
ROE:-118.82%
ROA:-23.29%
PB:4.59
PE(LYR):-1.75

Loading ...

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

GlobeNewswire
·
May 29

Editas Medicine preclinical data ‘looks highly supportive,’ says Evercore ISI

TIPRANKS
·
May 28

TD Cowen remains bullish on Editas Medicine after ‘compelling preclinical data’

TIPRANKS
·
May 28

BUZZ-Editas Medicine down after $125 mln stock-and-warrants offering

Reuters
·
May 26

Editas Medicine Announces Pricing of up to $319.4 Million Public Offering

THOMSON REUTERS
·
May 26

Editas Medicine Inc - Prices Public Offering of 55.56 Mln Shares and Warrants at $2.25 Each

THOMSON REUTERS
·
May 26

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

GlobeNewswire
·
May 26

Editas Medicine Suspends Existing At-The-Market Offering Prospectus

TIPRANKS
·
May 26

Editas Medicine Proposes Public Stock Offering; Shares Fall Pre-Bell

MT Newswires Live
·
May 26

Editas Showcases Promising EDIT-401 Data for Hyperlipidemia

TIPRANKS
·
May 26

Editas Medicine launches underwritten follow-on stock offering with warrants

Reuters
·
May 26

Editas Medicine Announces Proposed Public Offering

THOMSON REUTERS
·
May 26

Editas Medicine presented preclinical data for EDIT-401 at EAS Congress

TIPRANKS
·
May 26

Editas Medicine presents preclinical EDIT-401 data showing about 90% LDL-C reduction in primate study

Reuters
·
May 26

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

GlobeNewswire
·
May 26

Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT)

Simply Wall St.
·
May 15

JonesTrading Keeps Their Buy Rating on Editas Medicine (EDIT)

TIPRANKS
·
May 14

Editas Medicine Lead Therapy Cuts LDL Cholesterol by 90% in Preclinical Study

MT Newswires Live
·
May 14

Editas Medicine Reports New Preclinical Data Demonstrating Progress of Edit-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

THOMSON REUTERS
·
May 14

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

GlobeNewswire
·
May 14